Tonix Pharmaceuticals(TNXP)

Focus: Tonix Pharmaceuticals is a public specialty pharma company focused on CNS disorders, particularly neurology, with a commercial-stage product (TONMYA) and an active pipeline in fibromyalgia, PTSD, and chronic pain. The company operates with ~5,000 employees and maintains headquarters in Berkeley Heights, NJ.

Neurology

Profile data last refreshed 5h ago · AI intelligence enriched 4d ago

Funding Stage

PUBLIC

Employees

5000+

Open Jobs

5-8 this month

Cooling — net -8 jobs in 30d

4 added, 12 removed. Slower than typical.

Should You Work at Tonix Pharmaceuticals?

AI assessment

Tonix is a pre-profitability specialist with meaningful clinical catalysts ahead but substantial financial risk; best suited for risk-tolerant professionals betting on Phase 3 success and willing to accept volatile equity and constrained resources.

Why Work Here

Active Phase 3 pipeline in high-unmet-need areas (fibromyalgia, PTSD) with multiple development programs advancing simultaneously

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

11 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$10M

Key Products

TONMYA

Skeletal muscle spasm

Growth7.3yr

Lead commercial product; NDA approval enables revenue generation through 2034 with recent Medicare coverage expansion boosting market access.

Help build intelligence for Tonix Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Commercial launch of TONMYA (cyclobenzaprine HCl) in growth phase through 2034 LOE provides visibility into near-term revenue acceleration

Recent Medicare coverage expansion for TONMYA and new manufacturing facility groundbreaking signal operational scale-up and commercial momentum

Watch Out For

Severely cash-constrained: $99M cash (FY2025) against $40M annual R&D spend and negative net income of -$130M; burn rate limits hiring and strategic flexibility
Minimal revenue base ($10M FY2025) relative to R&D intensity (396%) creates high dependency on pipeline success; limited product diversification beyond cyclobenzaprine formulations

Generated by Claude from Tonix Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Cyclobenzaprine hydrochloride

Skeletal muscle spasm

Post-LOE